Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MRModerna, Inc. logo

Moderna, Inc. (MRNA)

NASDAQ Global Select · Currency in USD
$200.10 ▼ -2.53 (-1.25%)
At close: Oct 23, 4:00 PM ET. Market closed.
$201.29 ▲ +1.19 (+0.59%)
After hours: Oct 23, 7:59 PM ET

Summary

Previous Close
$202.63
Open
$196.69
Day's Range
$183.00 – $206.97
52 Week Range
$22.28 – $254.48
Volume
21,466,203
Avg. Volume
17,196,899
Market Cap
$79.89B
Beta (5Y Monthly)
0.90
PE Ratio (TTM)
--
EPS (TTM)
-$7.96
Earnings Date
Nov 6, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$117.40

Profile: Moderna, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
4,700
CEO
Stéphane Bancel

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah.

Earnings

Next report: Fri, Nov 6, 2026
EPS estimate -$1.11 · Revenue est. $891.34M
DateEst.Actual
Jul 31, 2026-$2.03-$1.97Beat
May 1, 2026-$4.45-$3.40Beat
Feb 13, 2026-$2.54-$2.11Beat
Nov 6, 2025-$1.87-$0.51Beat
Aug 1, 2025-$2.99-$2.13Beat
May 1, 2025-$2.92-$2.52Beat

Analyst view

Consensus price target
$117.40 ▼ -41.3%
Range $25.00 – $245.00
Rating: Hold
Buy 28% · Hold 52% · Sell 21%

Get free alerts on MRNA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.